BIOGNOSYS
15.6.2021 08:02:08 CEST | Business Wire | Press release
Biognosys, a leader in next-generation proteomics solutions for life sciences research and development, announced today the launch of Spectronaut 15 . The software provides fast, robust, and seamless data analysis for mass spectrometry (MS) based data-independent acquisition (DIA) proteomics . Thus, Spectronaut enables the investigation of protein expression, function, and structure across all major biological species and sample types.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210614005013/en/
Spectronaut is a commercial software for industry and academia and is also used as part of Biognosys' discovery proteomics contract research services. In conjunction with the company's proprietary, patented Hyper Reaction Monitoring (HRM™) technology, Spectronaut enables reproducible and precise quantification of up to 10,000 proteins in large-scale studies . The software employs advanced Search, Artificial Intelligence (AI), and Machine Learning (ML) algorithms to translate data into actionable insights for R&D and clinical research.
Since its first release in 2003, Spectronaut is continuously improving and always supports the newest technologies in data acquisition. The 15th generation of the software comes with an array of novel features and updates , such as:
- Significant improvements to directDIA, the industry-leading library-free DIA workflow
- A more comprehensive toolset for post-translational modification (PTM) analysis
- Improved deep learning augmentation for immunopeptidomics and ion mobility data analysis
- Powerful data visualization in an intuitive user interface
"With this new Spectronaut release, we offer our software users and service customers once more a higher level of performance, user experience, and insights to support their discovery proteomics research", said Biognosys CTO Lukas Reiter, PhD .
Spectronaut lead developer Oliver M. Bernhardt will share more details on the new features during the Spectronaut 15 launch webinar , Expand Biological insights with DIA Proteomics , held today at 5 PM CEST. Beyond that, Guest speaker Andreas-David Brunner will present a robust and scalable single-cell DIA proteomics workflow using ion mobility technology (dia-PASEF), developed at the Max Planck Institute of Biochemistry (Matthias Mann Lab).
Spectronaut 15 is fully vendor-independent and compatible with proteomics data acquired on instruments of all major mass spectrometer vendors.
Gary Kruppa, Vice President, Proteomics at Bruker Daltonics:
"Spectronaut has made it possible to implement our breakthrough dia-PASEF technology in many of our customer's facilities. With the latest Spectronaut release, the support for our ion mobility technology has seen a significant improvement, and we are looking forward to continuing our collaboration with Biognosys to maintain Spectronaut as a key solution for Bruker's DIA workflows."
Andreas Huhmer, Director Marketing, Mass Spectrometry Solutions at Thermo Fisher Scientific:
"Biognosys' Spectronaut is our software of choice to analyze DIA data in internal projects, including acquisition method development. Of course, it is also the solution we strongly recommend to our customers. Spectronaut has always been at the forefront when it comes to supporting our technology, and its ease of use and versatility makes it the best partner for DIA data analysis."
For more information about Spectronaut, including details about free trials and pricing, please visit biognosys.com/spectronaut .
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys' unique, patented technologies utilize high-resolution mass spectrometry for the quantification of thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at www.biognosys.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210614005013/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global Tech Sales Forecast to Reach $1.4 Trillion in 2026, Even as 56% of Consumers Delay Purchases, NIQ Finds1.9.2026 09:00:00 CEST | Press release
Global study finds price-sensitive shoppers will still pay more when products deliver clear, lasting benefits Global sales of consumer technology and durable goods are forecast to reach $1.4 trillion in 2026, up 5.1% year over year, even as 56% of consumers say they have delayed a technology purchase because of price or while waiting for a discount, according to new research from NIQ (NYSE: NIQ), the Official Global Insights Partner of IFA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901758503/en/ The era of automatic tech & durables upgrades is over. Released ahead of IFA 2026, which kicks off in Berlin on Sept. 4, 2026, NIQ today released its annual “State of Tech & Durables” report. Consumer Tech Trends 2027: How to Win When Every Purchase Must Be Justified examines how years of economic volatility have transformed technology purchasing behavior and what manufacturers and retailers must do to remain competitive. Key
Searchlight Capital Partners Announces Investment in Aderian Group1.9.2026 09:00:00 CEST | Press release
Partnership will support Aderian’s continued growth and expansion across the Nordic region Searchlight Capital Partners, L.P. ("Searchlight"), a leading global private investment firm, today announced an investment in Aderian Group ("Aderian" or the "Company"), a Nordic managed IT services provider serving more than 10,000 small and medium-sized enterprise ("SME") customers throughout Sweden and Norway. As part of the transaction, Aderian's management team will reinvest in the Company and remain meaningful shareholders alongside Searchlight, underscoring their continued commitment to Aderian's long-term growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901430715/en/ Aderian provides cloud, cybersecurity, AI and analytics, networking and modern workplace solutions. Since its founding in 2022, the Company has grown to approximately SEK 2.5 billion in revenue, with more than 850 employees and over 10,000 SME customers a
FluoSphera Licenses Debiopharm’s AbYlink™ Technology for 3D Antibody Characterization while Leveraging Leica Microsystems Viventis Deep Imaging Capabilities1.9.2026 09:00:00 CEST | Press release
New license agreement enables an integrated workflow combining antibody labeling, human-relevant 3D testing and quantitative imaging for antibody-based therapeutics Debiopharm (Debiopharm Research & Manufacturing), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases and FluoSphera, a Swiss biotechnology company developing advanced in vitro platforms to improve the prediction of drug efficacy and safety, today announced a new license agreement for use of AbYlink™, Debiopharm’s proprietary antibody conjugation technology. The agreement enables FluoSphera to offer biotechnology and pharmaceutical companies an integrated workflow combining regio-selective antibody labeling, high-throughput testing in human-relevant three-dimensional models and quantitative imaging analysis. The new offering is designed to support the characterization of antibody-drug conjugates (ADCs), bispecific antibodies, therape
Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer1.9.2026 08:30:00 CEST | Press release
Approval based on DESTINY-Breast09 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years Second approval for Enhertu in the EU in two months Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results fro
Paris Hilton Returns as the Face of KARL LAGERFELD as NOT-KARL Debuts for Fall–Winter 20261.9.2026 08:30:00 CEST | Press release
Following the success of the Maison's Fall-Winter 2025 and Spring-Summer 2026 campaigns, KARL LAGERFELD is delighted to announce the extension of its relationship with global entrepreneur, media personality and cultural icon Paris Hilton, continuing a partnership that has resonated with audiences around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831566835/en/ KARL LAGERFELD - Paris Hilton ©Matt Easton As the face of the Maison through Fall-Winter 2026 and Spring-Summer 2027, Paris Hilton returns for the next chapter of KARL LAGERFELD's From Paris With Love story, continuing to bring her signature confidence, wit and individuality. Photographed for the first time by Matt Easton, the Fall-Winter 2026 campaign introduces a new dimension to the narrative while remaining true to the House's established codes. At the heart of the Fall-Winter 2026 story, two masters of self-reinvention meet. Making his debut is NO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom